

DOXYCYCLINE BIOTECH 100 Film-coated tablets
(31/20.1.2/0425)

Response - Clinical
eCTD sequence: 0004

Each tablet contains doxycycline 100 mg

Date of submission: 11 October 2024

SCHEDULING STATUS

S4

1. NAME OF THE MEDICINE

DOXYCYCLINE BIOTECH 100, film-coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains doxycycline hyclate equivalent to doxycycline 100 mg.

Sugar free.

For full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Film-coated tablets

Round, light orange, film-coated, biconvex tablets, engraved “Dox” over “100” on one side and other side plain.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Infections caused by susceptible strains of pathogens:

Upper and lower respiratory tract infections:

Sinusitis, pharyngitis, Mycoplasma pneumonia, psittacosis and chronic bronchitis.

Genito-urinary tract infections:

DOXYCYCLINE BIOTECH 100 Film-coated tablets
(31/20.1.2/0425)

Response - Clinical
eCTD sequence: 0004

Each tablet contains doxycycline 100 mg

Date of submission: 11 October 2024

Non-specific urethritis (only if the strain is sensitive), lymphogranuloma venereum, chancroid and granuloma inguinale, gonococcal salpingitis, epididymitis, acute epididymo-orchitis, endocervical infections, syphilis and gonorrhoea (in cases of penicillin allergy).

Ophthalmic:

Trachoma and inclusion conjunctivitis.

Intestinal:

Cholera, Whipple's disease and tropical sprue.

Miscellaneous:

Rickettsial infections, brucellosis, tularaemia, actinomycosis, Lyme disease, yaws, relapsing fever, leptospirosis during the early infective phase.

4.2 Posology and method of administration

Posology

Adults

The usual dose is 100 mg twice daily on the first day, then 100 mg daily.

Paediatric population

DOXYCYCLINE BIOTECH 100 should not be used in children aged younger than 12 years due to the risk of teeth discolouration. (see section 4.3, 4.4 and 4.8).

DOXYCYCLINE BIOTECH 100 Film-coated tablets
(31/20.1.2/0425)

Response - Clinical
eCTD sequence: 0004

Each tablet contains doxycycline 100 mg

Date of submission: 11 October 2024

Method of administration

For oral administration

Should be taken either one hour before meals or two hours after meals.

Should be taken with adequate liquid and with the patient in the upright position, to avoid lodging of tablets in the distal oesophagus as this may result in local corrosive irritation and ulceration (see section 4.4 and 4.8).

4.3 Contraindications

- Hypersensitivity to doxycycline hyclate, other tetracyclines or to any of the excipients of DOXYCYCLINE BIOTECH 100 listed in section 6.1.
- In patients with impaired renal function.
- DOXYCYCLINE BIOTECH 100 should not be given in pregnancy. DOXYCYCLINE BIOTECH 100 crosses the placenta and are deposited in foetal bones and teeth (see section 4.6).
- Pregnant women are particularly susceptible to severe doxycycline-induced liver damage (see section 4.6).
- DOXYCYCLINE BIOTECH 100 should not be given to lactating women or to children younger than 12 years of age as permanent discolouration of the child's teeth may occur (see section 4.6).
- DOXYCYCLINE BIOTECH 100 should not be given to patients with systemic lupus erythematosus (see section 4.8).

4.4 Special warnings and precautions for use

Paediatric population

The use of medicines of the tetracycline class during tooth development (last half of pregnancy; infancy and childhood to the age of 12 years) may cause permanent discolouration of the teeth (yellow-grey-brown) (see

DOXYCYCLINE BIOTECH 100 Film-coated tablets
(31/20.1.2/0425)

Response - Clinical
eCTD sequence: 0004

Each tablet contains doxycycline 100 mg

Date of submission: 11 October 2024

section 4.3). This adverse reaction is more common during long-term use of the medicines but has been observed following repeated short-term courses. Enamel hypoplasia has also been reported.

Photosensitivity

Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines, including DOXYCYCLINE BIOTECH 100. Patients likely to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline medicines and treatment should be discontinued at the first evidence of skin erythema.

Photo onycholysis has also been reported in patients receiving DOXYCYCLINE BIOTECH 100 (see section 4.8).

Use in patients with impaired hepatic function

DOXYCYCLINE BIOTECH 100 should be used with caution in patients with liver function impairment. Abnormal hepatic function has been reported and has been caused by both the oral and parenteral administration of tetracyclines as contained in DOXYCYCLINE BIOTECH 100.

Frail or elderly patients are susceptible to the hepatotoxic and anti-anabolic effects of DOXYCYCLINE BIOTECH 100.

Do not use concomitantly with hepatotoxic medicines (see section 4.5).

Use in patients with renal impairment

Excretion of DOXYCYCLINE BIOTECH 100 by the kidney is about 40 %/72 hours in individuals with normal renal function. This percentage excretion may fall to a range as low as 1-5 %/72 hours in individuals with severe renal insufficiency (creatinine clearance below 10 mL/min). Studies have shown no significant difference in the

DOXYCYCLINE BIOTECH 100 Film-coated tablets
(31/20.1.2/0425)Response - Clinical
eCTD sequence: 0004

Each tablet contains doxycycline 100 mg

Date of submission: 11 October 2024

serum half-life of DOXYCYCLINE BIOTECH 100 in individuals with normal and severely impaired renal function.

Haemodialysis does not alter the serum half-life of doxycycline. The anti-anabolic action of the tetracyclines as contained in DOXYCYCLINE BIOTECH 100 may cause an increase in blood urea. Studies to date indicate that this anti-anabolic effect does not occur with the use of DOXYCYCLINE BIOTECH 100 in patients with impaired renal function.

Serious skin reactions

Serious skin reactions, such as exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in patients receiving DOXYCYCLINE BIOTECH 100 (see section 4.8). If serious skin reactions occur, DOXYCYCLINE BIOTECH 100 should be discontinued immediately, and appropriate therapy should be instituted.

Microbiological overgrowth

The use of antibiotics may occasionally result in over-growth of non-susceptible organisms, including *Candida*. If a resistant organism appears, the antibiotic should be discontinued and appropriate therapy instituted.

Pseudomembranous colitis

Pseudomembranous colitis has been reported with nearly all antibacterial medicines, including DOXYCYCLINE BIOTECH 100, and has ranged in severity from mild to life-threatening. It is important to consider this diagnosis in patients who present with diarrhoea after the administration of antibacterial medicines.

DOXYCYCLINE BIOTECH 100 Film-coated tablets
(31/20.1.2/0425)

Response - Clinical
eCTD sequence: 0004

Each tablet contains doxycycline 100 mg

Date of submission: 11 October 2024

Clostridium difficile associated diarrhoea (CDAD) has been reported with use of nearly all antibacterial medicines, including DOXYCYCLINE BIOTECH 100, and may range in severity from mild diarrhoea to fatal colitis. Treatment with antibacterial medicines alters the normal flora of the colon leading to overgrowth of *C. difficile*.

C. difficile produces toxins A and B, which contribute to development of CDAD. Hypertoxin producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD should be considered in all patients who present with diarrhoea after antibiotic treatment. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial medicines.

Oesophagitis

Oesophagitis and oesophageal ulcerations have been reported in patients receiving capsule and tablet forms of medicines in the tetracycline class, including DOXYCYCLINE BIOTECH 100. Most of these patients took medications immediately before going to bed or with inadequate amounts of fluid.

Porphyria

There have been rare reports of porphyria in patients receiving tetracyclines such as DOXYCYCLINE BIOTECH 100.

Benign intracranial hypertension

DOXYCYCLINE BIOTECH 100 Film-coated tablets
(31/20.1.2/0425)Response - Clinical
eCTD sequence: 0004

Each tablet contains doxycycline 100 mg

Date of submission: 11 October 2024

Bulging fontanelles in infants have been reported in individuals receiving tetracyclines. Benign intracranial hypertension (pseudotumor cerebri) has been associated with the use of tetracyclines including doxycycline (e.g., DOXYCYCLINE BIOTECH 100). Benign intracranial hypertension (pseudotumor cerebri) is usually transient, however cases of permanent visual loss secondary to benign intracranial hypertension (pseudotumor cerebri) have been reported with tetracyclines including doxycycline. If visual disturbance occurs during treatment, prompt ophthalmologic evaluation is warranted. Since intracranial pressure can remain elevated for weeks after medicine cessation patients should be monitored until they stabilise. Concomitant use of isotretinoin or other systemic retinoids and DOXYCYCLINE BIOTECH 100 should be avoided because isotretinoin is also known to cause benign intracranial hypertension (pseudotumor cerebri). (See section 4.5).

Venereal disease

When treating venereal diseases, where coexistent syphilis is suspected, proper diagnostic procedures, including darkfield examinations, should be utilised. In all such cases, monthly serological tests should be made for at least four months.

Beta-haemolytic streptococci infections

Infections due to Group A beta-haemolytic Streptococci should be treated for at least 10 days.

Myasthenia gravis

Due to a potential for weak neuromuscular blockade, care is advisable in patients with symptoms of myasthenia gravis as this may be aggravated in patients with this problem.

Systemic lupus erythematosus

DOXYCYCLINE BIOTECH 100 Film-coated tablets
(31/20.1.2/0425)

Response - Clinical
eCTD sequence: 0004

Each tablet contains doxycycline 100 mg

Date of submission: 11 October 2024

DOXYCYCLINE BIOTECH 100 should not be used in patients suffering from SLE (see section 4.3).

Jarisch-Herxheimer reaction

Some patients with spirochete infections may experience a Jarisch-Herxheimer reaction shortly after doxycycline (e.g., DOXYCYCLINE BIOTECH 100) treatment is started. Patients should be reassured that this is a usually self-limiting consequence of antibiotic treatment of spirochete infections.

Methoxyflurane

Caution is advised when DOXYCYCLINE BIOTECH 100 is used with methoxyflurane (see section 4.5).

The use of expired DOXYCYCLINE BIOTECH 100 may lead to a Fanconi-type syndrome which is characterised by polyuria and polydipsia with nausea, vomiting, proteinuria, glucosuria, acidosis, aminoaciduria, hypophosphatemia and hypocalcaemia (see section 4.8).

4.5 Interaction with other medicines and other forms of interaction

Absorption of DOXYCYCLINE BIOTECH 100 is diminished by milk, alkalis, aluminium hydroxide and other di and tri-valent cations such as calcium, iron, oral zinc, bismuth preparations and magnesium if they are given concomitantly. Dosages should be maximally separated.

There have been reports of prolonged prothrombin time in patients taking warfarin and DOXYCYCLINE BIOTECH 100. DOXYCYCLINE BIOTECH 100 depress plasma prothrombin activity therefore doses of anticoagulant may need to be reduced if given concomitantly.

DOXYCYCLINE BIOTECH 100 Film-coated tablets
(31/20.1.2/0425)

Response - Clinical
eCTD sequence: 0004

Each tablet contains doxycycline 100 mg

Date of submission: 11 October 2024

Phenobarbital, carbamazepine, primidone and phenytoin may increase the metabolism of DOXYCYCLINE BIOTECH 100 (reduces half-life). An increase in the daily dosage of DOXYCYCLINE BIOTECH 100 should be considered.

Penicillin should not be given concomitantly with DOXYCYCLINE BIOTECH 100 as antagonism in action may occur, since bacteriostatic medicines may interfere with the bactericidal action of penicillin.

DOXYCYCLINE BIOTECH 100 may diminish the effectiveness of oral contraceptives.

The concurrent use of DOXYCYCLINE BIOTECH 100 and methoxyflurane has been reported to result in serious nephrotoxicity.

Alcohol may decrease the half-life of DOXYCYCLINE BIOTECH 100.

DOXYCYCLINE BIOTECH 100 may increase the plasma concentration of ciclosporin. Co-administration should only be undertaken with appropriate monitoring.

Rifampicin that induces hepatic enzymes may accelerate the decomposition of DOXYCYCLINE BIOTECH 100, thereby decreasing its half-life. Sub-therapeutic doxycycline concentrations may result. Monitoring concurrent use is advised and an increase in DOXYCYCLINE BIOTECH 100 dose may be required.

DOXYCYCLINE BIOTECH 100 Film-coated tablets
(31/20.1.2/0425)

Response - Clinical
eCTD sequence: 0004

Each tablet contains doxycycline 100 mg

Date of submission: 11 October 2024

Concomitant use of isotretinoin or other systemic retinoids and DOXYCYCLINE BIOTECH 100 should be avoided. Each of these medicines used alone has been associated with benign intracranial hypertension (pseudotumor cerebri). (See section 4.4).

False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.

4.6 Fertility, pregnancy and lactation

Pregnancy

DOXYCYCLINE BIOTECH 100 should not be given in pregnancy. DOXYCYCLINE BIOTECH 100 crosses the placenta and are deposited in foetal bones and teeth (see section 4.3).

Pregnant women are particularly susceptible to severe doxycycline-induced liver damage (see section 4.3).

Breastfeeding

DOXYCYCLINE BIOTECH 100 should not be given to lactating women as permanent discolouration of the child's teeth may occur (see section 4.3).

4.7 Effects on ability to drive and use machines

Visual disturbances such as blurring of vision may occur during treatment with DOXYCYCLINE BIOTECH 100 and in such cases; patients must refrain from driving or operating machinery.

4.8 Undesirable effects

Tabulated summary of adverse reactions

MedDRA System Organ Class

DOXYCYCLINE BIOTECH 100 Film-coated tablets
(31/20.1.2/0425)

Response - Clinical
eCTD sequence: 0004

Each tablet contains doxycycline 100 mg

Date of submission: 11 October 2024

Infections and infestations		
<i>Frequent:</i>	<i>Less frequent:</i> Vaginal infection, candida infection	<i>Frequency unknown:</i>
Blood and lymphatic system disorders		
<i>Frequent:</i>	<i>Less frequent:</i> Haemolytic anaemia, neutropenia, thrombocytopenia, eosinophilia	<i>Frequency unknown</i>
Immune system disorders		
<i>Frequent:</i> Hypersensitivity reactions (including anaphylactic shock, anaphylactic reaction, anaphylactoid reaction, angioedema, exacerbation of systemic lupus erythematosus, pericarditis, serum sickness, Henoch-Schonlein purpura, hypotension, dyspnoea, tachycardia, peripheral oedema and urticaria)	<i>Less frequent:</i>	<i>Frequency unknown:</i>
Endocrine disorders		

DOXYCYCLINE BIOTECH 100 Film-coated tablets
(31/20.1.2/0425)

Response - Clinical
eCTD sequence: 0004

Each tablet contains doxycycline 100 mg

Date of submission: 11 October 2024

<i>Frequent:</i>	<i>Less frequent:</i> Brown-black microscopic discolouration of thyroid glands	<i>Frequency unknown:</i>
Metabolism and nutrition disorders		
<i>Frequent:</i>	<i>Less frequent:</i> Porphyria, decreased appetite	<i>Frequency unknown:</i> Vitamin deficiencies may occur
Nervous system disorders		
<i>Frequent:</i> Headache	<i>Less frequent:</i> Benign intracranial hypertension (pseudotumor cerebri)*, fontanelle bulging	<i>Frequency unknown:</i>
Psychiatric disorders		
<i>Frequent:</i>	<i>Less frequent:</i> Anxiety	<i>Frequency unknown:</i>
Ear and labyrinth disorders		
<i>Frequent:</i>	<i>Less frequent:</i> Tinnitus	<i>Frequency unknown:</i>
Vascular disorders		
<i>Frequent:</i>	<i>Less frequent:</i> Flushing	<i>Frequency unknown:</i>
Gastrointestinal disorders		
<i>Frequent:</i>	<i>Less frequent:</i>	<i>Frequency unknown:</i> Tooth discolouration

DOXYCYCLINE BIOTECH 100 Film-coated tablets
(31/20.1.2/0425)

Response - Clinical
eCTD sequence: 0004

Each tablet contains doxycycline 100 mg

Date of submission: 11 October 2024

Nausea, vomiting, enamel hypoplasia (usually only after long-term use), anorexia	Dyspepsia (heartburn/ gastritis), pancreatitis, pseudomembranous colitis, <i>Clostridium difficile</i> colitis, oesophageal ulcer, oesophagitis, enterocolitis, inflammatory lesions (with monilial overgrowth) in the anogenital region, dysphagia, abdominal pain, diarrhoea, glossitis, stomatitis	
Hepato-biliary disorders		
<i>Frequent:</i>	<i>Less frequent:</i> Hepatic failure, hepatitis, hepatotoxicity, jaundice, abnormal hepatic function	<i>Frequency unknown:</i>
Skin and subcutaneous tissue disorders		
<i>Frequent:</i> Photosensitivity reaction, rash including maculopapular and erythematous rashes, Jarisch-Herxheimer reaction (see section 4.4)	<i>Less frequent:</i> Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), toxic epidermal necrolysis, Stevens- Johnson syndrome, erythema multiforme,	<i>Frequency unknown:</i>

DOXYCYCLINE BIOTECH 100 Film-coated tablets
(31/20.1.2/0425)

Response - Clinical
eCTD sequence: 0004

Each tablet contains doxycycline 100 mg

Date of submission: 11 October 2024

	exfoliative dermatitis, photoonycholysis	
Musculoskeletal, connective tissue disorders		
<i>Frequent:</i>	<i>Less frequent:</i> Arthralgia, myalgia	<i>Frequency unknown:</i>
Renal and urinary disorders		
<i>Frequent:</i>	<i>Less frequent:</i> Increased blood urea	<i>Frequency unknown:</i>

* Symptoms included blurring of vision, scotomata and diplopia. Permanent visual loss has been reported.

^a Reversible and superficial discolouration of permanent teeth has been reported with the use of DOXYCYCLINE BIOTECH 100 but frequency cannot be estimated from available data.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare providers are asked to report any suspected adverse reactions to SAHPRA via the Med Safety APP (Medsafety X SAHPRA) and eReporting platform (who-umc.org) found on SAHPRA website.

4.9 Overdose

In the event of overdosage, appropriate supportive and symptomatic treatment is indicated.

Dialysis does not alter serum half-life and thus would not be of benefit in treating cases of overdosage.

DOXYCYCLINE BIOTECH 100 Film-coated tablets
(31/20.1.2/0425)
Each tablet contains doxycycline 100 mg

Response - Clinical
eCTD sequence: 0004
Date of submission: 11 October 2024

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

A 20.1.1 Antimicrobial (chemotherapeutic) agents. Broad and medium spectrum antibiotic.

Pharmacotherapeutic group: tetracyclines, ATC code: J01AA02

Doxycyclines are bacteriostatic antibiotics which inhibit bacterial growth by binding to the 30S ribosomal subunit with consequent misreading of information for protein synthesis. They are effective *in vitro* against the following organisms (*in vitro* activity does not necessarily imply *in vivo* efficacy):

Vibrio cholera, *Ureaplasma urealyticum*, *Mycoplasma pneumonia*, *Chlamydia trachomatis*, *Chlamydia psittaci*, *Borrelia recurrentis*, *Calymmatobacterium granulomatis*, *Borrelia burgdorferi*, penicillin-sensitive *Neisseria gonorrhoeae* and *Rickettsiae*.

Doxycyclines are also effective against the following organisms *in vitro*:

Haemophilus ducreyi, *Actinomyces israelii*, *Francisella tularensis*, *Treponema pertenue*.

Resistant pathogens

Many of the following strains are resistant:

Staphylococci

Enterococci

Proteus vulgaris

Fungi and yeasts (except Actinomyces)

Pseudomonas aeruginosa (all strains)

DOXYCYCLINE BIOTECH 100 Film-coated tablets
(31/20.1.2/0425)

Response - Clinical
eCTD sequence: 0004

Each tablet contains doxycycline 100 mg

Date of submission: 11 October 2024

E. coli

Shigella

Streptococcus

5.2 Pharmacokinetic properties

Doxycycline is readily and almost completely absorbed from the gastrointestinal tract. Peak plasma concentrations occur about 2 hours after ingestion. Doxycycline is readily absorbed into body fluids and tissues.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Colloidal silicon dioxide

Croscarmellose sodium

Magnesium Stearate

Microcrystalline cellulose

Tablet coating:

TC/530027 Orange which consist of:

Carnauba wax

Hypromellose

Polyethylene glycol/macrogol

Sunset yellow FCF aluminium lake

Titanium dioxide

6.2 Incompatibilities

DOXYCYCLINE BIOTECH 100 Film-coated tablets
(31/20.1.2/0425)
Each tablet contains doxycycline 100 mg

Response - Clinical
eCTD sequence: 0004
Date of submission: 11 October 2024

Not applicable

6.3 Shelf life

24 months

6.4 Special precautions for storage

Store at or below 25 °C in a well-closed container.

Protect from light.

6.5 Nature and contents of container

DOXYCYCLINE BIOTECH 100 tablets are packed in white, opaque, HDPE plastic bottles of 100 and 250.

DOXYCYCLINE BIOTECH 100 tablets are packed as blister strips of 14's in Alu/PVC strips.

Packs of 14's (1 x strip) or 28's (2 x strips) are available and further packed in an outer carton or patient ready pack.

All pack sizes and strengths may not necessarily be marketed at one time.

6.6 Special precautions for disposal and other handling

No special requirements.

7. HOLDER OF CERTIFICATE OF REGISTRATION

Biotech Laboratories (Pty) Ltd

Block K West, Central Park

400 16th Road,

DOXYCYCLINE BIOTECH 100 Film-coated tablets
(31/20.1.2/0425)
Each tablet contains doxycycline 100 mg

Response - Clinical
eCTD sequence: 0004

Date of submission: 11 October 2024

Midrand,

South Africa

1685

8. REGISTRATION NUMBER

31/20.1.1/0425

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of registration: 25 April 1997

10. DATE OF REVISION OF THE TEXT

03 March 2025.